Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Oxford Derivation, N. A, Consortia V, Oxford Derivation North American, V, Consortia V (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89(1):167–175

Article  CAS  PubMed  Google Scholar 

Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883–887

Article  CAS  PubMed  Google Scholar 

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15(1):157–163

Article  CAS  PubMed  Google Scholar 

Manno C, Torres DD, Rossini M, Pesce F, Schena FP (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24(12):3694–3701

Article  CAS  PubMed  Google Scholar 

Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H (2009) Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53(1):26–32

Article  CAS  PubMed  Google Scholar 

Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y (2020) Efficacy and safety of immunosuppressive monotherapy agents for IgA nephropathy: a network meta-analysis. Front Pharmacol 11:539545

Article  CAS  PubMed  Google Scholar 

Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28(4):441–449

Article  CAS  PubMed  Google Scholar 

Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D (2023) Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv 9(12):eadd6734

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, Investigators, STOP-IgAN Investigators (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225–2236

Article  CAS  PubMed  Google Scholar 

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V, Group, T. S (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318(5):432–442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Vecchio L, Marco A, Comolli S, Peiti S, Rimoldi C, Locatelli F (2024) Drugs in development to treat IgA nephropathy. Drugs. https://doi.org/10.1007/s40265-024-02036-1

Article  PubMed  Google Scholar 

Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402(10405):859–870

Article  CAS  PubMed  Google Scholar 

Lin Y, Jia J, Guo Y, He D, Zhang Y, Wang F, Yan T, Liu Y, Lin S (2018) Corticosteroid for IgA nephropathy: are they really therapeutic? Am J Nephrol 47(6):385–394

Article  CAS  PubMed  Google Scholar 

Pozzi C (2016) Treatment of IgA nephropathy. J Nephrol 29(1):21–25

Article  CAS  PubMed  Google Scholar 

Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2016) Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11(6):973–981

Article  PubMed  PubMed Central  Google Scholar 

Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, Group, T. S (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327(19):1888–1898

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y, Lv J, Zhang H (2017) Severe Adverse effects associated with corticosteroid treatment in patients with IgA nephropathy. Kidney Int Rep 2(4):603–609

Article  PubMed  PubMed Central  Google Scholar 

Julian BA, Barker C (1993) Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 104:198–206

Article  CAS  PubMed  Google Scholar 

Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H (2006) Japanese Pediatric Ig, A. N. T. S. G. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):511–517

Article  CAS  PubMed  Google Scholar 

Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, Suzuki H (2003) A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clin Exp Nephrol 7(1):48–51

Article  CAS  PubMed  Google Scholar 

DiBonaventura M, Nicolucci A, Meincke H, Le Lay A, Fournier J (2018) Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. Clinicoecon Outcomes Res 10:457–475

Article  PubMed  PubMed Central  Google Scholar 

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejia-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100(4):753–779

Article  PubMed  Google Scholar